Hirunorms are true hirudin mimetics. The crystal structure of human α- thrombin-hirunorm V complex

Protein Science

Volumn 7, Issue 2, 1998, Pages 243-253

  De Simone, Giuseppina ^a   Lombardi, Angela ^a   Galdiero, Stefania ^a   Nastri, Flavia ^a   Della Morte, Rossella ^b   Staiano, Norma ^b   Pedone, Carlo ^a   Bolognesi, Martino ^c,d   Pavone, Vincenzo ^a,e  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Ctro Interuniversitario Ric su P   (Italy)

Author keywords

Antithrombotics; Hirudin like binding mode; Hirunorms; Thrombin; Thrombin synthetic inhibitors; X ray crystal structure

Indexed keywords

HIRUDIN; HIRUNORM; HIRUNORM V; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CRYSTALLOGRAPHY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 0031890648     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560070203     Document Type: Article

References (73)

1. Abola EE, Bernstein FC, Bryant SH, Koetzle TF, Weng J. 1987. Protein Data Bank. In: Allen FH, Bergerhoff G, Sievers R, eds. Crystallographic databases - Information content, software systems, scientific applications. Bonn/Cambridge/Chester: Data Commission of the International Union of Crystallography. pp 107-132.
2. Ascenzi P, Amiconi G, Bode W, Bolognesi M, Coletta M, Menegatti E. 1995. Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: Structural functional and biomedical aspects. Mol Aspects Med 16:215-313.
3. Banner DW, Hadvary P. 1991. Crystallographic analysis at 30 Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 266:20085-20093.
4. Bar-Shavit R, Kahn A, Wilner GD, Mann KG, Fenton JW II. 1984. Localization of a chemotactic domain in human thrombin. Biochemistry 23:397-400.
5. Berliner LJ. 1992. Thrombin structure and function. New York: Plenum Press.
6. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. 1977. The Protein Data Bank: A computer-based archival file for macromolecular structures. J Mol Biol 112:535-542.
7. Bode W, Huber R. 1992. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:443-452.
8. Bode W, Huber R, Rydel TJ, Tulinsky A. 1992a. X-ray crystal structures of human α-thrombin and of human thrombin-hirudin complex. In: Berliner LJ, ed. Thrombin structure and function. New York: Plenum Press.
9. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. 1989. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg-chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 8:3467-3475.
10. Bode W, Turk D, Karshikov A. 1992b. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1:426-471.
11. Brandstetter H, Turk D, Hoeffken HW, Grosse D, Stürzebecher J, Martin PD, Edwards BFP, Bode W. 1992. Refined 2.3 Å X-ray crystal structure of bovine trombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP 4-TAPAP and MQPA. J Mol Biol 226:1085-1099.
12. CCP4. 1994. The CCP4 suite: Programs for protein crystallography Acta Crystallogr D 50:760-767.
13. Davie EW, Fujikawa K, Kisiel W. 1991. The coagulation cascade: Initiation maintenance and regulation. Biochemistry 30: 10364-10370.
14. DiMaio J, Gibb B, Munn D, Lefebre J, Ni F, Konishi Y. 1991. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Lett 282:47-52.
15. DiMaio J, Gibb B, Lefebre J, Konishi Y, Munn D, Yue SY. 1992. Synthesis of a homogeneous series of ketomethylene arginyl pseudopeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem 35:3331-3341.
16. Engh RA, Huber R. 1991. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr A 47:392-400.
17. Engh RA, Brandstetter H, Sucher G, Eichinger A, Baumann U, Bode W, Huber R, Poll T, Rudolph R, von der Saal W. 1996. Enzyme flexibility solvent and "weak" interactions characterize thrombin-ligand interactions: Implication for drug design. Structure 4:1353-1362.
18. Fenton JW II. 1986. Thrombin. Ann NY Acad Sci 485:5-15.
19. Fenton JW II, Bing DH. 1986. Thrombin active-site regions. Semin Thromb Haemostasis 12:200-208.
20. Fenton JW II, Ofosu FA, Moon DG, Maraganore JM. 1991. Thrombin structure and function: Why thrombin is the primary target for antithrombotics. Blood Coag Fibrinol 2:69-75.
21. Fenton JW II, Olson TA, Zabinski MP, Wilner GD. 1988. Anion binding exosite of human α-thrombin and fibrinogen recognition. Biochemistry 27:7106-7112.
22. Féthière J, Tsuda Y, Coulombe R, Konishi Y, Cygler M. 1996. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human α-thrombin. Protein Sci 5:1174-1183.
23. Grütter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. 1990. Crystal structure of the thrombin-hirudin complex: A novel mode of serine proteinase inhibition. EMBO J 9:2361-2365.
24. Iwanowicz E, J Lau WF, Lin J, Roberts DGM, Seiler SM. 1994. Retro-binding tripeptide thrombin active-site inhibitors: Discovery synthesis and molecular modeling. J Med Chem 37:2122-2124.
25. Jakubowski JA, Maraganore JM. 1990. Inhibition of coagulation and thrombin induced platelet activities by a synthetic dodecapeptide modeled on the carboxy terminus of hirudin. Blood 75:399-406.
26. Jones TA, Zou JY, Cowan S, Kieldgaard M. 1991. Improved methods for building protein models in electron density maps and location of errors in these models. Acta Crystallogr A 47:110-119.
27. Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara N, Ninomiya K, Hijikata A, Okamoto S. 1984. Selective inhibition of thrombin by 2R,4R-4-methyl-1-N2-[3-methyl-1,2,3,4-tetrahydro-8-quinolinyl sulphonyl-L-arginyl]-2-piperidine-carboxylic. Biochemistry 23:85-89.
28. Kline T, Hammond C, Bourdan P, Maraganore J. 1991. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Commun 177:1049-1055.
29. Krishnan R, Tulinsky A, Vlasuk GP, Pearson D, Vallar P, Bergum P, Brunck TK, Ripka WC. 1996. Synthesis structure and structure-activity relationships of divalent thrombin inhibitors containing an α-keto-amide transition state mimetic. Protein Sci 5:422-433.
30. Krstenansky JL, Broersma RJ, Owen TJ, Payne MH, Yates MT, Mao SJ. 1990a. Development of MDL 28050 a small antithrombin agent based on a functional domain of the leech protein hirudin. Thromb Haemostasis 63:208-214.
31. α-acetyl-hirudin 45-65. FEBS Lett 211:10-16.
32. Krstenansky JL, Owen TJ, Yates MT, Mao SJT. 1987. Anticoagulant peptides: Nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site of thrombin. J Med Chem 30:1688-1691.
33. Krstenansky JL, Owen TJ, Yates MT, Mao SJT. 1988. Design synthesis and antithrombin activity for conformationally restricted analogs of peptide anticoagulants based on the C-terminal region of the leech peptide hirudin. Biochim Biophys Acta 957:53-59.
34. Krstenansky JL, Owen TJ, Yates MT, Mao SJT. 1990b. The C-terminal binding domain of hirullin P18 antithrombic activity and comparison to hirudin peptides. FEBS Lett 269:425-429.
35. Laskowski M, Kato I. 1980. Protein inhibitors of proteinases. Annu Rev Biochem 49:593-626.
36. Leslie AGW. 1992. Joint CCP4 and ESF-EACBM newsletter on protein crystallography no. 26. Warrington, UK: Daresbury Laboratory.
37. Lombardi A, Nastri F, Della Morte R, Rossi A, De Rosa A, Staiano N, Pedone C, Pavone V. 1996. Rational design of true hirudin mimetics: Synthesis and characterization of multisite-directed α-thrombin inhibitors. J Med Chem 39:2008-2017.
38. Malley MF, Tabernero L, Chang CY, Ohringer SL, Roberts DGM, Das J, Sack JS. 1996. Crystallographic determination of the structures of human α-thrombin complexed with BMS-186282 and BMS-189090. Protein Sci 5:221-228.
39. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JWII. 1990. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095-7101.
40. Markwardt F. 1994. The development of hirudin as an antithrombotic drug. Thrombosis Res 74:1-23.
41. Maryanoff BE, Qiu X, Padmanabhan KP, Tulinsky A, Almond HR Jr, Andrade-Gordon P, Greco MN, Kauffman JA, Nicolau KC, Liu A, Brungs PH, Fusetani N. 1993. Molecular basis for the inhibition of human α-thrombin by the macrocyclic peptide cyclotheonamide A. Proc Natl Acad Sci USA 90:8048-8052.
42. Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Isshii M, Chen J, Turck CW, Coughlin SR. 1994. Crystallographic structures of thrombin complexed with thrombin receptor peptides: Existence of expected and novel binding modes. Biochemistry 33:3266-3279.
43. Nakanashi H, Chrusciel RA, Sheen R, Bertenshaw S, Johnson ME, Ryedel TJ, Tulinsky A, Kahn M. 1992. Peptide mimetics of the thrombin-bound structure of fibrinopeptide A. Proc Natl Acad Sci USA 89:1705-1709.
44. α-NN-dimethylcarbamoyl-α-azalysine p-nitrophenyl ester: A comparative kinetic and X-ray crystallographic study. J Mol Biol 258:851-859.
45. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara N, Ninomiya K, Maruyama A, Sugano M, Tamao Y. 1981. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereostructure of its carboxamide portion. Biochem Biophys Res Commun 101:440-446.
46. Priestle JP, Rahuel J, Rink H, Tones M, Grütter MG. 1993. Changes in interaction in complexes of hirudin derivatives and human α-thrombin due to different crystal forms. Protein Sci 2:1630-1642.
47. Qui X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, Maraganore JM, Fenton JW II. 1992. Structures of hirulog 3-thrombin complex and nature of S′ subsites of substrates and inhibitors. Biochemistry 31:11689-11697.
48. Qiu X, Yin M, Padmanabhan KP, Krstenansky JL, Tulinsky A. 1993. Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. J Biol Chem 268:20318-20326.
49. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. 1990. The structure of a complex of recombinant hirudin and human α-thrombin. Science 249:277-280.
50. Rydel TJ, Tulinsky A, Bode W, Huber R. 1991. Refined structure of the hirudin-thrombin complex. J Mol Biol 221:583-601.
51. Salemme FR, Spurlino J, Bone R. 1997. Serendipity meets precision: The integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Structure 5:319-324.
52. Schechter I, Berger A. 1967. On the size of the active site in proteinases I papain. Biochem Biophys Res Commun 27:157-162.
53. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM. 1991. Structure of hirugcn and hirulog 1 complexes of α-thrombin. J Mol Biol 221:1379-1393.
54. Stone SR, Hofsteengc J. 1986. Kinetic of the inhibition of thrombin by hirudin. Biochemistry 25:4622-4628.
55. Stubbs MT, Bode W. 1993. A player of many parts: The spotlight falls on thrombin's structure. Thromb Res 69:1-58.
56. Stubbs MT, Bode W. 1995. Structure and specificity in coagulation and its inhibition. Trends Cardiovasc Med 5:157-166.
57. Stubbs MT, Oschkinat H, Mayr I, Huber R, Angliker H, Stone SR, Bode W. 1992. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem 206:187-195.
58. Stura EA, Wilson IA. 1992. Seeing techniques. In: Ducruix A, Giegé R, eds. Crystallization of nucleic acids and proteins: A practical approach. Oxford, UK: Oxford University Press. pp 99-126.
59. Stürzebecher J, Markwardt F, Voigt B, Wagner G. 1984. Inhibition of bovine and human thrombins by derivatives of benzamidines. Thromb Res 36:457-467.
60. Stürzebecher J, Markwardt F, Voigt B, Wagner G, Walsmann P. 1983. Cyclic amides of Na-arylsulfonylamino acylated 4-amidinophenylalanine - Tight binding of thrombin. Thromb Res 29:635-642.
61. Szewczuk Z, Gibbs BF, Yue SY, Purisima E, Zdanov A, Cygler M, Konishi Y. 1993. Design of a linker for trivalent thrombin inhibitors: Interaction of the main chain of the linker with thrombin. Biochemistry 32:3396-3404.
62. Tabernero L, Chang CY, Ohringer SL, Lau WF, Iwanowicz EJ, Han W, Wang TC, Seiler SM, Roberts DGM, Sack JS. 1995. Structure of a retro-binding peptide inhibitor complexed with human α-thrombin. J Mol Biol 246:14-20.
63. Tollefsen DM, Feagler JR, Majerus PW. 1974. The binding of thrombin to the surface of human platelets. J Biol Chem 249:2646-2651.
64. Tronrud D, TenEyck LF, Matthews BW. 1987. An efficient general purpose least squares refinement program for macromolecular structures. Acta Crystallogr A 34:489-501.
65. Tsuda Y, Cygler M, Gibbs BF, Pedyczac A, Féthière J, Vue SY, Konishi Y. 1994. Design of potent bivalent thrombin inhibitors based on hirudin sequence: Incorporation of nonsubstrate-type active site inhibitors. Biochemistry 33:14443-14451.
66. Tulinsky A, Qiu X. 1993. Active site and exosite binding of α-thrombin. Blood Coagulation and Fibrinolysis 4:305-312.
67. van de Locht A, Lamba D, Bauer M, Huber R, Friedrich T, Kröger B, Höffken W, Bode W. 1995. Two heads are heiter than one: Crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J 14:5149-5157.
68. van de Locht A, Stubbs MT, Bode W, Friedrich T, Bollschweiler C, Höffken W, Huber R. 1996. The ornithodorin-thrombin crystal structure a key to the TAP enigma? EMBO J 15:6011-6017.
69. Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. 1994. The isomorphous structure of prethrombin 2 hirugen- and PPACK-thrombin: Changes accompanying activation and exosite binding to thrombin. Protein Sci 3:2254-2271.
70. Vitali J, Martin PD, Malkowski MD, Robertson WD, Lazar JB, Winant RC, Johnson PJ, Edwards BFP. 1992. The structure of a complex of bovine α-thrombin and recombinant hirudin at 2.8 Å resolution. J Biol Chem 267:17670-17678.
71. Vu TKH, Wheaton VI, Hung DT, Charo I, Coughlin SR. 1991. Domains specifying thrombin receptor interaction. Nature 353:674-677.
72. Wu TP, Yee V, Tulinsky A, Chrusciel RA, Nakanashi H, Shen R, Priebe C, Kahn M. 1993. The structure of a designed peptidomimetic inhibitor complex of α-thrombin. Protein Eng 6:471-478.
73. Zdanov A, Wu S, DiMaio J, Konishi Y, Li Y, Wu X, Edwards BFP, Martin PD, Cygler M. 1993. Crystal structure of the complex of human α-thrombin and nonhydrolyzable bifunctional inhibitors hirutonin-2 and hirutonin-6. Proteins Struct Funct Genet 17:252-265.